How should incidental NEN of the pancreas and gastrointestinal tract be followed?

R Ariotti, S Partelli, F Muffatti, V Andreasi, F della Sala, M Falconi

Research output: Contribution to journalArticlepeer-review


Neuroendocrine gastro-entero-pancreatic neoplasms (GEP-NENs) constitute a heterogeneous group of tumors, whose incidence has increased over the years. The most frequent site for primary disease is the stomach followed by small and large intestine, and pancreas. In the last decade, a dramatic growing in the incidence of small, incidental GEP-NENs has been recorded. In parallel, an increasing attitude toward more conservative approaches instead of surgical management has being widely spreading. This is particularly true for small, asymptomatic, pancreatic NEN as for these tumor forms an active surveillance has proven to be safe and feasible. Primary site and biological features of the neoplasms lead to different strategies and indications for surveillance and follow-up. This review focuses on the current evidence on modality and timing of surveillance and conservative treatment of incidentally discovered lesions. © 2018 Springer Science+Business Media, LLC, part of Springer Nature
Original languageEnglish
Pages (from-to)139-144
Number of pages6
JournalReviews in Endocrine and Metabolic Disorders
Issue number2
Publication statusPublished - 2018


Dive into the research topics of 'How should incidental NEN of the pancreas and gastrointestinal tract be followed?'. Together they form a unique fingerprint.

Cite this